Is ofatumumab safe?
Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.
Is ofatumumab a chemotherapy?
Ofatumumab is the generic name for the trade chemotherapy drug Arzerra. In some cases, health care professionals may use the trade name Arzerra when referring to the generic drug name Ofatumumab. Drug Type: Ofatumumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.
What does ofatumumab treat?
Ofatumumab injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells) in adults who have not gotten better after treatment with fludarabine (Fludara) and alemtuzumab (Campath).
Is Arzerra chemotherapy?
Arzerra is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.
Is ofatumumab FDA approved?
Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting …
How is ofatumumab administered?
Administration Instructions: • Do not mix ARZERRA with, or administer as an infusion with, other medicinal products. Administer using an infusion pump and an administration set. Flush the intravenous line with 0.9% Sodium Chloride Injection, USP before and after each dose. Start infusion within 12 hours of preparation.
Is ofatumumab a biologic?
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.
Is ofatumumab approved in MS?
Ofatumumab has been approved for adults with active relapsing MS. Active disease is defined by MRI scans that identify inflammation or new or enlarging lesions.
Is Kesimpta the same as Ocrevus?
The safety and efficacy data of Ocrevus is, overall, comparable with that of Kesimpta. The main differentiation between the two drugs is the delivery system and the annual cost of therapy, which is $65,000 for Ocrevus compared to $83,000 for Kesimpta in the US.
Does Kesimpta treat PPMS?
Novartis is not planning to open a clinical trial of Kesimpta (ofatumumab) as a potential treatment for primary progressive multiple sclerosis (PPMS) anytime soon, a company executive said. But it is well aware of the “unmet need” for therapy options among this patient group, and is exploring avenues.